PC
CHRS icon

Prairiewood Capital’s Coherus Oncology CHRS Stock Holding History

Prairiewood Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-52,292
Closed -$764K – 69
2021
Q1 		$764K Buy
52,292
+2,464
+5% +$41.8K 0.7% 41
2020
Q4 		$866K Buy
+49,828
New +$887K 0.88% 35

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Prairiewood Capital's CHRS Position: Q2 2021 in Review

Prairiewood Capital sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 52,292 shares — an estimated $764K sold.

Prairiewood Capital first reported a position in CHRS in Q4 2020 and held it in 2 quarters. The position peaked at $866K in Q4 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

  • Prairiewood Capital reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
  • Prairiewood Capital sold 52,292 Coherus Oncology shares in Q2 2021, an estimated $764K.
  • Prairiewood Capital first reported a position in Coherus Oncology in Q4 2020 and held it in 2 quarters.
  • Prairiewood Capital's Coherus Oncology position peaked at $866K in Q4 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Prairiewood Capital's 13F filing for Q2 2021, filed 13 Jul 2021.